Drug / Drugs / Medicine / Europe / Europe blog main / Europe top stories / Indiana blog main / Indiana top stories / National blog main / New York blog main / New York top stories / Biotech / Boehringer Ingelheim / clinical trials / Eli Lilly / empagliflozin / FDA / Life Sciences / SLGT2 inhibitor / Type 1 diabetes / Type 2 Diabetes

FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes

Posted On: Mar 24, 2020   |   Posted By: Xconomy

FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes

A type 2 diabetes drug marketed by Boehringer Ingelheim and Eli Lilly has fallen short of a bid to expand the medicine's approval to patients who have type 1 diabetes. The FDA on Friday rejected the application for the drug, empagliflozin , for use in addition to insulin as a treatment for type 1 diabetes in adults. Boehringer Ingelheim and Lilly did not detail the agency's rationale for denying the application. Last November, an FDA advisory committee voted 14 to 2 against recommending approval of the drug, saying the drug's benefits do not outweigh its safety risks. Type...

Continue reading ...